Trader consensus implies an 89.5% probability that the CDC will not issue any Level 4 "Avoid All Travel" Travel Health Notice for a disease by December 31, 2026, driven by the absence of severe, life-threatening outbreaks warranting this rare designation—none are currently active per CDC surveillance. Recent epidemiological data, including the latest weekly influenza report showing no new human cases of avian A(H5N1) with person-to-person transmission and global polio alerts limited to Level 1 or 2, reinforces stability without extreme risks. Meningococcal disease outbreaks noted in late March remain below thresholds for escalation. While novel pathogens could emerge, controlled transmission dynamics and historical precedents post-COVID support the low odds of a Level 4 issuance, with ongoing CDC monitoring key ahead of year-end.
Polymarketデータを参照したAI生成の実験的な要約 · 更新日はい
新規
新規
2026/12/31
はい
新規
新規
2026/12/31
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.Trader consensus implies an 89.5% probability that the CDC will not issue any Level 4 "Avoid All Travel" Travel Health Notice for a disease by December 31, 2026, driven by the absence of severe, life-threatening outbreaks warranting this rare designation—none are currently active per CDC surveillance. Recent epidemiological data, including the latest weekly influenza report showing no new human cases of avian A(H5N1) with person-to-person transmission and global polio alerts limited to Level 1 or 2, reinforces stability without extreme risks. Meningococcal disease outbreaks noted in late March remain below thresholds for escalation. While novel pathogens could emerge, controlled transmission dynamics and historical precedents post-COVID support the low odds of a Level 4 issuance, with ongoing CDC monitoring key ahead of year-end.
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
マーケット開始日： Jan 19, 2026, 3:15 PM ET
音量
$0終了日
2026/12/31マーケット開始日
Jan 19, 2026, 3:15 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.Trader consensus implies an 89.5% probability that the CDC will not issue any Level 4 "Avoid All Travel" Travel Health Notice for a disease by December 31, 2026, driven by the absence of severe, life-threatening outbreaks warranting this rare designation—none are currently active per CDC surveillance. Recent epidemiological data, including the latest weekly influenza report showing no new human cases of avian A(H5N1) with person-to-person transmission and global polio alerts limited to Level 1 or 2, reinforces stability without extreme risks. Meningococcal disease outbreaks noted in late March remain below thresholds for escalation. While novel pathogens could emerge, controlled transmission dynamics and historical precedents post-COVID support the low odds of a Level 4 issuance, with ongoing CDC monitoring key ahead of year-end.
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
音量
$0終了日
2026/12/31マーケット開始日
Jan 19, 2026, 3:15 PM ETResolver
0x65070BE91...Trader consensus implies an 89.5% probability that the CDC will not issue any Level 4 "Avoid All Travel" Travel Health Notice for a disease by December 31, 2026, driven by the absence of severe, life-threatening outbreaks warranting this rare designation—none are currently active per CDC surveillance. Recent epidemiological data, including the latest weekly influenza report showing no new human cases of avian A(H5N1) with person-to-person transmission and global polio alerts limited to Level 1 or 2, reinforces stability without extreme risks. Meningococcal disease outbreaks noted in late March remain below thresholds for escalation. While novel pathogens could emerge, controlled transmission dynamics and historical precedents post-COVID support the low odds of a Level 4 issuance, with ongoing CDC monitoring key ahead of year-end.
Polymarketデータを参照したAI生成の実験的な要約 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問